Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple blood test allow uveitis patients to safely take less medication?

NCT ID NCT06390436

Not yet recruiting Disease control Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial investigates whether people with chronic non-infectious uveitis—an eye condition that can cause blindness—can safely reduce their dose of adalimumab (a drug that calms the immune system) by using regular blood tests to monitor drug levels. Participants whose uveitis has been stable for at least 48 weeks will either continue standard dosing or follow a dose-spacing schedule guided by their blood drug concentration. The goal is to see if the lower-dose strategy is as effective at preventing eye inflammation while potentially reducing side effects and treatment burden.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Adalimumab
What this could lead to
If successful, this could show that many patients with stable uveitis can safely take less adalimumab, reducing side effects and costs without losing disease control.
What could go wrong
This is a Phase 4 trial, so adalimumab is already approved. The main risk is that reducing the dose might lead to a flare-up of uveitis in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Disease uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC DISEASE UVEITIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • APHP - Centre hospitalier national des Quinze-Vingts

    Paris, 75012, France

  • APHP - Hôpital Cochin

    Paris, 75014, France

  • APHP - Hôpital Pitié-Salpétrière

    Paris, 75013, France

  • CH Avignon

    Avignon, 84000, France

  • CH Le Puy-en-Velay

    Le Puy-en-Velay, 43000, France

  • CHU Grenoble Alpes

    Grenoble, 38700, France

  • CHU MONTPELLIER - Hôpital Saint-Eloi

    Montpellier, 34090, France

  • Chu Montpied

    Clermont-Ferrand, 63003, France

  • Chu de Saint-Etienne

    Saint-Etienne, 42055, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • HCL - Hôpital Edouard Herriot

    Lyon, France

  • Hôpital de la Croix Rousse

    Lyon, 69317, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.